Movement Disorders Unit, Neurology Department, Hospital of Santa Creu and Sant Pau, Barcelona.
Sant Pau Biomedical Research Institute, Barcelona.
Ann Neurol. 2019 Nov;86(5):762-769. doi: 10.1002/ana.25581. Epub 2019 Aug 31.
To longitudinally evaluate the role of depression in the development of impulse control disorders (ICDs) in Parkinson disease (PD) patients.
Using data from the Parkinson's Progression Markers Initiative, we included PD patients without ICDs at baseline according to the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). Patients were prospectively evaluated first quarterly and then biannually. Development of an ICD was defined as an increase in QUIP scores during follow-up. Using survival proportional hazard models, we studied the effect of baseline depression on ICD risk. We also evaluated this effect controlling for dopamine agonist use as a time-dependent variable and for other potential confounders.
Among 354 patients, 68 were depressed at baseline. The median follow-up was 4.08 years. Depression at baseline was associated with higher ICD risk (hazard ratio [HR] = 1.96, 95% confidence interval [CI] = 1.32-2.9, p < 0.001). This risk remained significant after controlling for dopamine agonist use (HR = 1.97, 95% CI = 1.33-2.9, p < 0.001), which was also independently linked to ICD development (HR = 1.87, 95% CI = 1.3-2.7, p < 0.001). Therefore, depressed patients faced an even higher ICD risk when receiving dopamine agonists. Controlling for multiple potential confounders did not alter these results.
Depression predisposes to the development of ICDs in PD. This risk is magnified by dopamine agonists. Dopamine agonists should thus be used cautiously in depressed PD patients. ANN NEUROL 2019;86:762-769.
纵向评估抑郁在帕金森病(PD)患者冲动控制障碍(ICD)发展中的作用。
利用帕金森进展标志物倡议的数据,我们根据帕金森病冲动-强迫问卷(QUIP)纳入基线时无 ICD 的 PD 患者。患者前瞻性地每季度评估一次,然后每半年评估一次。ICD 的发展定义为随访期间 QUIP 评分的增加。使用生存比例风险模型,我们研究了基线抑郁对 ICD 风险的影响。我们还评估了这种效果,控制了多巴胺激动剂的使用作为时变变量以及其他潜在的混杂因素。
在 354 名患者中,有 68 名患者在基线时抑郁。中位随访时间为 4.08 年。基线时的抑郁与更高的 ICD 风险相关(风险比 [HR] = 1.96,95%置信区间 [CI] = 1.32-2.9,p < 0.001)。在控制多巴胺激动剂的使用后,这种风险仍然显著(HR = 1.97,95% CI = 1.33-2.9,p < 0.001),多巴胺激动剂的使用也与 ICD 的发展独立相关(HR = 1.87,95% CI = 1.3-2.7,p < 0.001)。因此,接受多巴胺激动剂治疗的抑郁患者面临更高的 ICD 风险。控制多个潜在混杂因素并没有改变这些结果。
抑郁使 PD 患者更容易发生 ICD。这种风险在使用多巴胺激动剂时会进一步放大。因此,在抑郁的 PD 患者中应谨慎使用多巴胺激动剂。